First trimester screening for Down syndrome using free β hCG, total hCG and PAPP-A:: an exploratory study

被引:17
作者
Wright, Dave [1 ]
Spencer, Kevin
Nix, Barry [2 ]
机构
[1] Univ Plymouth, Plymouth PL4 8AA, Devon, England
[2] Cardiff Univ, Cardiff, Wales
关键词
Down syndrome; screening; first trimester;
D O I
10.1002/pd.1844
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective To investigate the potential utility of first trimester screening for Down syndrome using Free beta-hCG, total hCG and PAPP-A. Materials and Methods Using estimates from the literature, a simulation study was undertaken to estimate the performance of tests incorporating, Free beta-hCG, total hCG and PAPP-A at gestations of 8-12 weeks. We used sensitivity analysis to assess the effect of departures from the assumed model. Results We estimate that detection rates in excess of 75% for a false positive rate (FPR) of 3% can be achieved with first trimester measures of PAPP-A, total hCG and Free beta-hCG at 8 weeks-the addition of total hCG adding 11%. Detection rates of around 90% for a FPR of 3% can be achieved through the inclusion of nuchal translucency (NT) at 12 weeks to these early first trimester biochemical markers. Our analysis indicates that the marginal benefit of adding total hCG diminishes rapidly with gestational age and that there is little benefit from adding total hCG later than 10 weeks of gestation. Conclusion The performance of first trimester screening using early combinations of total hCG, Free beta-hCG and PAPP-A should be assessed in further studies. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:1118 / 1122
页数:5
相关论文
共 12 条
  • [1] Meta-analysis of first trimester Down syndrome screening studies:: free β-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol
    Evans, Mark I.
    Krantz, David A.
    Hallahan, Terrence W.
    Galen, Robert S.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 196 (03) : 198 - 205
  • [2] First-trimester or second-trimester screening, or both, for Down's syndrome
    Malone, FD
    Canick, JA
    Ball, RH
    Nyberg, DA
    Comstock, CH
    Bukowski, R
    Berkowitz, RL
    Gross, SJ
    Dugoff, L
    Craigo, SD
    Timor-Tritsch, IE
    Carr, SR
    Wolfe, HM
    Dukes, K
    Bianchi, DW
    Rudnicka, AR
    Hackshaw, AK
    Lambert-Messerlian, G
    Wald, NJ
    D'Alton, ME
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) : 2001 - 2011
  • [3] Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening
    Nicolaides, KH
    Spencer, K
    Avgidou, K
    Faiola, S
    Falcon, O
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2005, 25 (03) : 221 - 226
  • [4] *OFF NAT STAT, 2002, BIRTH STAT SER FMI
  • [5] Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: A validation study
    Palomaki, Glenn E.
    Wright, David E.
    Summers, Anne M.
    Neveux, Louis M.
    Meier, Christian
    O'Donnell, Andrea
    Huang, Tianhua
    Knight, George J.
    Haddow, James E.
    [J]. PRENATAL DIAGNOSIS, 2006, 26 (08) : 730 - 739
  • [6] Spencer K, 2000, PRENATAL DIAG, V20, P311, DOI 10.1002/(SICI)1097-0223(200004)20:4<311::AID-PD809>3.0.CO
  • [7] 2-P
  • [8] Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
    Spencer, K
    Bindra, R
    Nix, ABJ
    Heath, V
    Nicolaides, KH
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2003, 22 (02) : 142 - 148
  • [9] The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome
    Spencer, K
    Crossley, JA
    Aitken, DA
    Nix, ABJ
    Dunstan, FDJ
    Williams, K
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 : 219 - 231
  • [10] Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy
    Spencer, K
    Crossley, JA
    Aitken, DA
    Nix, ABJ
    Dunstan, FDJ
    Williams, K
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2002, 39 : 567 - 576